Abiopharma

Sale of Non-Core Businesses

FLSmidth: Transactions under share buy-back programme

Register of shareholders, changes and capital status – final redemption of commercial papers (series 2) according to their terms.

Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026

Dividend in the amount of 243 agorot per share, record date 29.6.26, payment 15.7.26

Roundtable Launches Real-Time, AI/DeFi Payment Platform

Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026

Approval of a purchase plan

Change in holdings of interested parties/officers

General Announcement: Net Asset Value ("NAV") as of 19 June 2026